A B S T R A C T To investigate the gene-dosage effect in familial hypercholesterolemia (FH), metabolic studies were conducted in a group of well-characterized patients with either heterozygous (n = 7) or homozygous (n = 7) FH and the results were compared to those obtained in normal subjects (n = 6). 524 these seven patients is caused by variation in the plasma apoLDL synthetic rates. Consistent with this conclusion was the finding that the correlation between the plasma LDL level and the apoLDL synthetic rates in the seven FH homozygotes was 0.943.
A B S T R A C T To investigate the gene-dosage effect in familial hypercholesterolemia (FH), metabolic studies were conducted in a group of well-characterized patients with either heterozygous (n = 7) or homozygous (n = 7) FH and the results were compared to those obtained in normal subjects (n = 6). The turnover of 1251-labeled low-density lipoprotein (LDL) was measured in all of the normals, all but one of the FH heterozygotes, and in all of the homozygotes. Chemical cholesterol balance was performed simultaneously with the 125I-LDL turnover in all seven of the homozygotes.
With regard to 1251-LDL turnover, FH homozygotes, who possess two doses ofthe mutant FH gene, exhibited a threefold increase in the rate of apoLDL synthesis while the fractional catabolic rate (FCR) for the apoprotein was only about one-third of normal. Heterozygotes, who have only one dose of the mutant FH gene, exhibited intermediate values for both parameters; that is, the FCR was two-thirds of normal and the apoLDL synthetic rate was 1.7-fold greater than normal.
The data indicate that the single gene defect in FH produces two distinct abnormalities ofLDL metabolism: (a) an increase in the synthetic rate for apoLDL and (b) a decrease in the efficiency of apoLDL catabolism. Both defects are more severe in FH homozygotes than in heterozygotes.
The FCR for apoLDL in the homozygotes appeared to be fixed at 17%/d whereas the plasma LDL level varied about twofold. These findings suggest that the twofold variation in plasma LDL levels observed in Dr. Bilheimer is an Established Investigator of the American Heart Association.
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The rate of total body cholesterol synthesis determined by chemical cholesterol balance did not appear to clearly differ between normals and patients with either one or two mutant FH genes. Two of the youngest FH homozygotes exhibited cholesterol overproduction but the other five did not. No consistent abnormality of bile acid metabolism was observed in these patients. Because the daily plasma flux of cholesterol on LDL is about threefold greater than the amount of cholesterol produced per day, a significant amount ofthe cholesterol liberated from LDL degradation must be reused. INTRODUCTION Familial hypercholesterolemia (FH)1 is a common inherited disorder of plasma lipoprotein metabolism that causes increased low-density lipoprotein (LDL) concentrations in the plasma (1, 2) . FH (3, 7) . Fibroblasts from FH homozygotes express an absence or near-absence of LDL receptor activity and therefore show no highaffinity degradation of LDL (3, 4) .
The question then arises: how is this receptor abnormality translated in vivo into a two-to threefold elevation in plasma LDL levels in FH heterozygotes and a four-to eightfold elevation in FH homozygotes? Early studies ofplasma 1251-LDL turnover in FH heterozygotes indicated that the fractional catabolic rate (FCR) for LDL was reduced by _60% in these subjects as compared to normals (8) , whereas the synthetic rate for LDL was the same in the heterozygotes and in the normal controls (8) . Subsequent studies of 125I-LDL turnover in FH homozygotes indicated that these subjects exhibited a dual defect: the FCR for LDL was reduced to about one-third of normal, whereas LDL production was up to fourfold greater than normal (9) (10) (11) .
These previous 125I-LDL turnover studies involved FH heterozygotes and homozygotes studied in different laboratories. Moreover, these studies were performed before the recognition that patients with FH can have any of at least three different mutations at the LDL receptor locus. One of these, termed (Rbo), specifies a receptor that does not bind LDL in detectable amounts (4) . Another of these alleles (Rb-) specifies a receptor that can bind up to 10% of the normal amount of LDL (12) . The third allele (Rb+, i°) specifies a receptor that can bind but not transport LDL into cells for degradation (13, 14) .
In the current study, we have compared 1251-LDL metabolism in a series of intact subjects with welldefined types of FH. In addition, we have studied total body cholesterol synthesis in these patients by the sterol balance technique. The results indicate that there are proportional abnormalities in LDL metabolism consistent with a gene-dosage effect that influences both LDL synthesis and LDL degradation.
METHODS
Patients. The study included 20 subjects. Six were normolipidemic, seven had heterozygous FH, and seven had homozygous FH. The six normal subjects were free-living individuals who responded to a general request for normal volunteers to participate in the lipoprotein turnover study. Five were Caucasian and one (J.Ch.) was an American Indian. Routine clinical laboratory tests indicated that these individuals were free of diabetes mellitus, thyroid disease, hepatic disease, or renal dysfunction. The pertinent clinical data for these subjects are outlined in Table I .
The FH heterozygotes were selected either because they were parents of a homozygous child or because they were members of a kindred with heterozygous FH. Both M.M. and J.C. were mothers of homozygous children (J.M. and M.C., respectively), K.M. was the sister of a homozygote (J.M.), and the other four patients were members of a large kindred with FH that was previously reported (7) . Pertinent clinical data on these patients is included in Table I . Data on two additional young heterozygotes (L.C. and Je.Ch.) have been previously reported (11) but are included in Tables I, III , and IV to permit ready comparisons.
The pertinent clinical data concerning the patients with homozygous FH are contained in Table II .
Informed consent was obtained from each patient and, when necessary, from his or her parent or guardian.
Diets. The normal subjects and four of the patients with heterozygous FH (R.M., B.O., M.B., and C.C.) were studied while consuming an isocaloric diet containing 20% of the calories as protein, 40% as fat, and 40% as carbohydrate. The cholesterol content was limited to 300 mg/d and the polyunsaturate-to-saturate fat ratio was _1.5.
Those patients participating in a chemical cholesterol balance either alone or simultaneously with a 125I-LDL turnover study consumed an isocaloric, low cholesterol, partial solid food diet to facilitate the balance study. This diet was formulated from a lard base as previously described (15) , and on average, contained 19% of the calories as protein, 37% as fat, and 44% as carbohydrate. The cholesterol content is listed in Table IV .
Lipoprotein turnover studies. 10-14 d after admission to the metabolic ward, plasma was obtained from each patient by plasmapheresis with standard citrate-phosphate-dextrose anticoagulant and then dialyzed for 24 h against 12 liters of solution containing 0.15 M NaCl, 0.1% EDTA, pH 7.4 (d = 1.006 g/ml). Details for the preparation of the 125I-LDL have been published (11) . The efficiency of iodination ranged between 8 and 37%. The degree of lipid labeling of the 1251-LDL determined by chloroform:methanol extraction (2:1, vol/vol) varied between 0.6 and 7.5%. Greater than 97% ofthe radioactivity in the 125I-LDL was precipitated with TCA and the 1251-LDL was indistinguishable from native LDL electrophoretically (16) , immunologically (17) , and biologically as determined by its ability to suppress 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts (18) .
Each lipoprotein turnover study was initiated by injecting autologous 125I-LDL through a running intravenous line kept open with normal saline. From 0.3 to 6.0 mg of LDL protein was injected in a volume not exceeding 2 ml. The amount of radioactivity injected varied directly with the body weight and ranged from 12.5 to 50 ,uCi. Plasma volume was calculated by the isotope dilution technique with the 10-min sample (8) . Serial blood samples and 24-h urine collections were obtained and analyzed as previously reported (11, 19) . Plasma and urine samples were assayed for radioactivity in a Packard Model 5285 Autogamma scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.).
The kinetic parameters for LDL turnover were calculated as described (11) . The apoLDL concentration was calculated from the measured value for LDL-cholesterol and the measured ratio of protein to cholesterol in each patient's LDL. During the 125I-LDL turnover study, each patient received 500-700 mg of iodine daily in divided doses in the form of a saturated solution of potassium iodide (8) .
Measurement ofplasma cholesterol and triglyceride levels. These measurements were made as described (11) Measurement of plasma lipoproteins. Lipoprotein concentrations in plasma were estimated by standard techniques as described (11) .
Cholesterol balance studies. Chemical cholesterol balance was performed according to described methods with ,8-sitosterol and chromium oxide as intemal standards (15, 20) .
Serial 4-d stool collections were performed while the patients were consuming the lard-base diet. The stools were frozen until the study was completed; each collection was then homogenized, and aliquots were taken for sterol analyses with the Kruskal-Wallis analysis of variance followed by the nonparametric multiple comparisons procedure (21) .
RESULTS
Evidencefora metabolic steady state. Several lines of evidence suggest that each patient maintained a relatively steady metabolic state during each study. First, calorie intake was constant as reflected by the absence of any significant weight change (Tables I and  II) . Second, plasma lipids in each patient showed little variation throughout the study (Tables I and II) . Third, fecal steroid excretion in each of the patients studied by sterol balance was relatively constant during each study (Table IV) .
LDL turnover in normal subjects. The mean age (8, 11) . When the absolute rate of synthesis of apoLDL was normalized for body weight, the mean synthetic rate was 8.0+0.7 mg/kg per d. Of the total amount of apoLDL in the body, 60.5±6.7% was calculated to be in the intravascular space. There were no obvious differences between the sexes with regard to the principal apoLDL turnover parameters (half-life, FCR, synthetic rate, and the percent total apoLDL in the body contained within the intravascular space) 2 The LDL-cholesterol in all three study groups was measured on the d = 1.019-1.063 fraction of plasma LDL. in this group but the number of observations for each sex was small.
The inclusion of one American Indian in the group of normals deserves comment because members of certain Indian tribes may have lower plasma cholesterol levels than do Caucasians. Although the total plasma cholesterol level was low in subject J.Ch., his LDL turnover parameters did not differ from the range of values observed in the normal Caucasians. Furthermore, if the results in this subject were excluded from the statistical analyses, none ofthe subsequent conclusions involving comparison with the other groups were altered (data not shown).
LDL turnover in FH heterozygotes. The mean age and body weight of the heterozygotes did not differ significantly from these parameters in the normal group (Table I) . None of the subjects was obese. The unique feature of the heterozygotes was that four of the six were members of the same pedigree, and the other two were obligate heterozygotes in that they were mothers of FH homozygotes. Hence, the likelihood that the hypercholesterolemia in these six patients was caused by the FH gene was extremely high. The total plasma and LDL-cholesterol levels in this group were significantly elevated above normal, whereas the high-density lipo- Fraction of the intravascular apoLDL pool metabolized each day, calculated either from the two exponentials of the plasma die-away curve (c) or from the U:P ratio (d).
Percentage of total body apoLDL contained in the intravascular space. From reference 11. I P < 0.05.
protein (HDL)-cholesterol and plasma triglyceride levels were not (Table I) . Although the heterozygotes were slightly older than the normal subjects, the difference in the average age between these two groups was not significant. The mean plasma apoLDL concentration in the heterozygotes was 2.6-fold greater than normal.
The mean half-life of the second exponential of the apoLDL die-away curve for the heterozygotes was 4.5+0.8 d, a value slightly greater than but not significantly different from normal. The mean FCR was significantly reduced from normal (Table III) and once again the mean FCR calculated from the plasma dieaway curve (0.287±0.040/d) agreed closely with the mean value derived from the U/P ratio (0.296+0.051/d). The finding of a reduced FCR in the heterozygotes confirmed the findings of previous reports (8, 11, 23) . The mean value for apoLDL synthesis normalized for body weight was 1.7-fold greater than normal in the heterozygotes and only one of the six heterozygotes had an apoLDL synthetic rate in the normal range. The increased apoLDL synthetic rate in the heterozygotes was significantly different from normal (Table III) . Subjects M.M. and J.C. consumed lard-based partial formula diets during their lipoprotein turnover studies to determine whether or not this diet would markedly influence LDL turnover parameters. As can be seen from the data in Table III The close relationship between the apoLDL synthetic rate and the plasma apoLDL concentration in the homozygotes is evident from the plot in Fig. 1 . A high degree of correlation exists between the apoLDL synthetic rate and the plasma apoLDL concentration (r = 0.943). This high degree of correlation is expected when one considers the narrow range of values for the FCR in these patients and points out that the FCR is not the only major determinant of pool size in these patients. A highly significant correlation was also found when the apoLDL synthetic rate was compared to the plasma apoLDL concentration in the heterozygotes (r = 0.86; data not shown), again because of the relatively narrow range through which the FCR fluctuates in this group (Table III) .
Chemical cholesterol balance. Seven FH homozygotes and four FH heterozygotes were evaluated by chemical cholesterol balance (Table IV) . The heterozygotes were selected as "controls" of similar age for the young homozygotes because virtually no chemical cholesterol balance data are available in normal children of this age group. The results in M.C., L.C., and (11) . Individual values are listed in Table III. Je.Ch. were presented in an earlier report (11) . Table  IV also contains the summary of unpublished results of chemical cholesterol balance studies in 14 normal adult males performed in San Diego under conditions identical to those employed here. The age range for these subjects was 27-63 yr with a mean age of 50 yr. All patients excreted sterol in excess of their dietary intake, and because there was no reason to suppose that they were losing body cholesterol this excess excretion of sterol represents a minimal estimate for the amount of total cholesterol synthesized per day. As we reported (11), M.C. exhibited a total cholesterol synthetic rate of 22.2 mg/kg per d, a value approximately twofold greater than normal. Although the percentage of newly synthesized cholesterol converted to bile acids in this patient was relatively low (1.9%), her absolute production rate for bile acids (4.3 mg/kd per d) was in the range of the "control subjects."
An increased synthetic rate for J.M. was also apparent (16.6 mg/kg per d), but in this case 69.3% of the total sterol production was in the form of bile acids (11.5 (23) . Because the FH homozygotes overproduced apoLDL by threefold in the steady state, their absolute catabolic rate for apoLDL was also increased by threefold. In this setting the reduced fractional catabolic rate might reflect the saturation of normal catabolic pathways rather than the altered clearance of apoLDL by faulty cell surface receptors. Several lines of evidence suggest that the decreased FCR results from altered clearance of apoLDL caused by abnormal receptor activity. First, the FCR for LDL appears to be fixed in FH homozygotes at -17%/d. Thus, among FH homozygotes whose plasma apoLDL levels varied from 250 to 569 mg/dl, the FCR showed little variation from the mean of 17%/d, whereas the absolute synthetic and degradative rate for LDL varied nearly threefold (15.6-41.6 mg/kg per d), indicating that the variation in plasma LDL levels observed in these patients is caused by the variation in the plasma apoLDL synthetic rates (Fig. 1) . Second, a similar phenomenon was seen in FH heterozygotes in whom the values for apoLDL synthetic rates varied widely (Table II) . Third, observations that portacaval shunt surgery ( Fig. 1) (11) and plasmapheresis (24) (3, 14) . The mechanism by which a deficiency of LDL receptors causes an increased synthesis of LDL has not been defined. It has been postulated on the basis of genetic reasoning that an LDL receptor may normally exist on liver cells and that one of its functions is to monitor the plasma level of LDL and to suppress production of that lipoprotein (10, 25, 26) or its precursor, very low-density lipoprotein (VLDL). The absence of such an LDL receptor in liver cells of FH homozygotes would cause the liver to sense a deficiency of LDL in plasma and thereby to secrete the lipoprotein directly into plasma (10, 25, 26) . Indeed, recent studies by Soutar et al. (27) show that in FH homozygotes, in contrast to normal subjects, a considerable portion of LDL is secreted directly into plasma without passing through VLDL. With respect to cholesterol synthesis as determined by the sterol balance technique, the current data show no clear-cut differences between normals and patients with either one or two FH genes. Previous studies using techniques similar to those employed in this study have also failed to demonstrate a difference in sterol balance between normal and presumptive FH heterozygotes (28) (29) (30) (31) (32) . Metabolic studies of cholesterol turnover (33) and cholesterol balance (11, 34, 35) in FH homozygotes have not yielded consistent or significant abnormalities in the rate of total body cholesterol production. Of the six homozygotes previously studied (11, (33) (34) (35) , three had increased synthesis (17.0, 17.1, and 22.2 mg/kg per d), whereas the other three exhibited normal cholesterol production. There was no clear reason for this difference although those patients with increased synthesis were younger (7, 10, and 12 yr) than the other patients (14, 15 , and 18 yr), and sterol production and excretion may be increased in children as compared to adults (36) .
Two of our FH homozygotes exhibited low values for bile acid synthesis. Low bile acid synthesis has been observed by others in some patients with FH (37) (38) (39) but it is unlikely that this inconstant finding plays a role in the pathogenesis of this disease for several reasons. First, cholestyramine treatment increases fecal bile acid excretion in FH homozygotes to the same degree as it does in normal subjects (40) . Second, complete biliary diversion increased bile acid excretion markedly in two FH homozygotes without altering the plasma cholesterol level (41) . Third, feeding bile acids to patients with FH does not materially influence the plasma cholesterol level (42) .
In the face of a normal rate of total, body cholesterol (Table IV) which equals 931 mg/d in a 70-kg man. In this example, the amount ofLDL-cholesterol transported through the plasma space each day is threefold greater than the total amount produced daily by the body.
